These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 17178635)

  • 1. Pharmacokinetic study of darbepoetin alfa: absorption, distribution, and excretion after a single intravenous and subcutaneous administration to rats.
    Yoshioka E; Kato K; Shindo H; Mitsuoka C; Kitajima SI; Ogata H; Misaizu T
    Xenobiotica; 2007 Jan; 37(1):74-90. PubMed ID: 17178635
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Population pharmacokinetics meta-analysis of recombinant human erythropoietin in healthy subjects.
    Olsson-Gisleskog P; Jacqmin P; Perez-Ruixo JJ
    Clin Pharmacokinet; 2007; 46(2):159-73. PubMed ID: 17253886
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics of darbepoetin alfa after intravenous or subcutaneous administration in patients with non-myeloid malignancies undergoing chemotherapy.
    Heatherington AC; Dittrich C; Sullivan JT; Rossi G; Schueller J
    Clin Pharmacokinet; 2006; 45(2):199-211. PubMed ID: 16485917
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lymphatic absorption of subcutaneously administered proteins: influence of different injection sites on the absorption of darbepoetin alfa using a sheep model.
    Kota J; Machavaram KK; McLennan DN; Edwards GA; Porter CJ; Charman SA
    Drug Metab Dispos; 2007 Dec; 35(12):2211-7. PubMed ID: 17875672
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Absorption, distribution and excretion of radioactivity by male rats after a single intravenous or subcutaneous dose of 14C-azacitidine.
    Ichikawa T; Suda Y; Nakagawa T; Nonaka K; Nakamura A; Ochi S
    Drug Res (Stuttg); 2013 Feb; 63(2):84-9. PubMed ID: 23447079
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Exposure-response modeling of darbepoetin alfa in anemic patients with chronic kidney disease not receiving dialysis.
    Doshi S; Chow A; Pérez Ruixo JJ
    J Clin Pharmacol; 2010 Sep; 50(9 Suppl):75S-90S. PubMed ID: 20881221
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacodynamics, pharmacokinetics, and tolerability of intravenous or subcutaneous GC1113, a novel erythropoiesis-stimulating agent.
    Han H; Lee J; Shin D; Shin KH; Jeon H; Lim KS; Yoon SH; Shin SG; Jang IJ; Cho JY; Yu KS
    Clin Drug Investig; 2014 Jun; 34(6):373-82. PubMed ID: 24623104
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Studies on the metabolism and disposition of the new retinoid 4-[(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthyl)carbamoyl] benzoic acid. 1st communication: absorption, distribution, metabolism and excretion after topical application and subcutaneous administration in rats.
    Mizojiri K; Okabe H; Sugeno K; Esumi Y; Takaichi M; Miyake T; Seki H; Inaba A
    Arzneimittelforschung; 1997 Jan; 47(1):59-69. PubMed ID: 9037446
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Darbepoetin alfa (KRN321) administered intravenously once monthly maintains hemoglobin levels in peritoneal dialysis patients.
    Hiramatsu M; Kubota M; Iwasaki M; Akizawa T; Koshikawa S;
    Ther Apher Dial; 2008 Feb; 12(1):19-27. PubMed ID: 18257808
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Studies on the metabolism and disposition of the new retinoid 4-[(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthyl)carbamoyl] benzoic acid. 2nd communication: absorption, distribution and excretion after single and consecutive subcutaneous administration in rats.
    Mizojiri K; Okabe H; Sugeno K; Esumi Y; Takaichi M; Tsutsumi S; Harada T; Miyoshi R; Inaba A
    Arzneimittelforschung; 1997 Feb; 47(2):195-200. PubMed ID: 9079240
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Randomized equivalence study evaluating the possibility of switching hemodialysis patients receiving subcutaneous human erythropoietin directly to intravenous darbepoetin alfa.
    Chazot C; Terrat JC; Dumoulin A; Ang KS; Gassia JP; Chedid K; Maurice F; Canaud B;
    Ann Pharmacother; 2009 Feb; 43(2):228-34. PubMed ID: 19407262
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics of the new thyrotropin releasing hormone analogue montirelin hydrate. 2nd communication: distribution and transfer into the fetus and milk after a single intravenous administration and pharmacokinetics and enzyme induction after repeated intravenous administration to rats.
    Sugimoto T; Hayashi T; Okita A; Morino A
    Arzneimittelforschung; 1996 Feb; 46(2):114-27. PubMed ID: 8720299
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Darbepoetin alfa effectively maintains haemoglobin concentrations at extended dose intervals relative to intravenous or subcutaneous recombinant human erythropoietin in dialysis patients.
    Brunkhorst R; Bommer J; Braun J; Haag-Weber M; Gill C; Wagner J; Wagener T;
    Nephrol Dial Transplant; 2004 May; 19(5):1224-30. PubMed ID: 14993489
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A comparison of haemoglobin levels and doses in haemodialysis patients treated with subcutaneous or intravenous darbepoetin alfa: a German prospective, randomized, multicentre study.
    Bommer J; Asmus G; Wenning M; Bommer G
    Nephrol Dial Transplant; 2008 Dec; 23(12):4002-8. PubMed ID: 18676350
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Population pharmacokinetics of darbepoetin alpha in peritoneal dialysis and non-dialysis patients with chronic kidney disease after single subcutaneous administration.
    Kawakami K; Takama H; Nakashima D; Tanaka H; Uchida E; Akizawa T
    Eur J Clin Pharmacol; 2009 Feb; 65(2):169-78. PubMed ID: 18807251
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of pain and efficacy of darbepoetin alfa and epoetin Beta pegol treatment in patients receiving peritoneal dialysis.
    Otsuka T; Sakai Y; Yui S; Sukegawa M; Suzuki A; Mugishima K; Sumi Y; Otsuka Y; Tsuruoka S
    J Nippon Med Sch; 2015; 82(1):21-6. PubMed ID: 25797871
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics of darbepoetin alfa after single, intravenous or subcutaneous administration in Japanese pediatric patients with chronic kidney disease.
    Uemura O; Hattori M; Hataya H; Ito S; Ito N; Akizawa T
    Clin Exp Nephrol; 2014 Dec; 18(6):932-8. PubMed ID: 24504705
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Detection of darbepoetin alfa misuse in urine and blood: a preliminary investigation.
    Morkeberg J; Lundby C; Nissen-Lie G; Nielsen TK; Hemmersbach P; Damsgaard R
    Med Sci Sports Exerc; 2007 Oct; 39(10):1742-7. PubMed ID: 17909401
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetics of 4-acetylaminophenylacetic acid. 1st communication: absorption, distribution, metabolism and excretion in mice, rats, dogs and monkeys after single administration of 14C-labeled compound.
    Sugihara K; Morino A; Nomura A; Iida S; Sugiyama M
    Arzneimittelforschung; 1990 Jul; 40(7):800-5. PubMed ID: 2222556
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Absorption, distribution and excretion of [carbonyl-14C]mosapride citrate after a single oral administration in rats, dogs and monkeys.
    Matsumoto S; Tagawa M; Amejima H; Nakao M; Kagemoto A; Fujii T; Miyazaki H; Sekine Y
    Arzneimittelforschung; 1993 Oct; 43(10):1084-94. PubMed ID: 8267675
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.